[DOI] [PubMed] [Google Scholar] 77.Thway K., Hamarneh W., Miah A.B., Fisher C
To be an eligible candidate, patients should be in good health with a BMI below 35, and ideally below 30 for optimal outcomes
A.YildizK.et al
Clinical studies provide direct evidence: GLP-1 analogue therapy significantly reduced sCD163 (a marker of inflammatory macrophage activation), independent of changes in body weight, fructosamine, and HbA1c
The data encompass a wide range of care settings and include patient demographics, diagnoses, procedures, medications (ordered, administered, and dispensed), laboratory and vital sign measurements, and social determinants of health (e.g., education and income, when available)
As such, liver disease may lead to increased ROS production and, subsequently, increased peroxidation of lipid membranes and inflammatory factors production, leading to hepatocyte injury and cell death (6063)